Lidaprim Forte (Sulfametrole, Trimethoprim)

The sulfonamide component blocks dihydropteroate synthase, preventing synthesis of dihydropteroic acid, while trimethoprim inhibits dihydrofolate reductase. This dual blockade disrupts bacterial folic‑acid metabolism, halting DNA synthesis and producing a bacteriostatic effect against susceptible organisms.

The dosage of Lidaprim Forte is individualized by the prescribing clinician based on the infection being treated, patient age, renal and hepatic function, and local antimicrobial guidelines. Patients should follow the exact regimen provided by their healthcare professional.

Safety data for sulfametrole/trimethoprim in pregnancy are limited, and the combination is generally avoided unless the potential benefit justifies the risk. It is excreted in breast milk, so caution is advised for nursing mothers, and a healthcare provider should assess the risk‑benefit ratio.

To request Lidaprim Forte, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with single‑agent sulfonamides, the sulfametrole/trimethoprim combination offers broader coverage and synergistic inhibition of folic‑acid synthesis, often resulting in lower resistance rates. Relative to other oral antibiotics such as amoxicillin, it provides effective activity against certain Gram‑negative pathogens but shares a similar safety profile regarding sulfonamide‑related reactions.

Lidaprim Forte should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Lidaprim Forte is taken orally, usually with a full glass of water. It may be taken with or without food, but taking it with meals can reduce gastrointestinal upset. Patients should swallow tablets whole and not crush or chew them unless specifically instructed.

Serious adverse events include Stevens‑Johnson syndrome, toxic epidermal necrolysis, severe neutropenia, hemolytic anemia, hepatic dysfunction and acute renal impairment. Prompt medical attention is required if patients develop widespread rash, blistering, fever, unexplained bruising, jaundice or a sudden decrease in urine output.

Lidaprim Forte is contraindicated in individuals with a known hypersensitivity to sulfonamides, trimethoprim, or any component of the formulation. It should also be avoided in patients with severe renal or hepatic impairment unless dose adjustments are made, and in pregnant women unless the therapeutic benefit outweighs potential risks.